Here’s what you need to know.
1. The company’s GI products include: Linzess, Viberzi, Asacol/Delzicol, Carafate/Sulcrate, Canasa/Salofalk and Zenpep.
2. In the third quarter, Allergan reported revenues of $431.4 million in 2016 compared to $398.6 million in 2015.
3. All Allergan GI products except Asacol/Delzicol reported positive growth.
More articles on gastroenterology/endoscopy:
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
GI leader to know: Dr. Carl Gessner of LeBauer HealthCare
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.